OncLive TV

Dr Doroshow on RET Inhibitors in RET Fusion+ NSCLC

August 4th 2023

Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.

Dr Massarelli on NTRK Inhibitors in NTRK Fusion+ NSCLC

August 4th 2023

Erminia Massarelli MD, PhD, MS, discusses efficacy and safety data with the NTRK inhibitors larotrectinib and entrectinib in patients with non–small cell lung cancer harboring NTRK fusions.

Dr Abdou on Treatment Sequencing With CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

August 4th 2023

Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Bloomer on the Rationale for the ColoCare Study in Newly Diagnosed CRC

August 4th 2023

Amanda Bloomer, PhD, discusses the rationale for launching the ColoCare study, an investigation into the health-related quality of life outcomes of younger vs older adult patients with newly diagnosed colorectal cancer.

Dr Frank on Sequencing Questions With CAR22 in Relapsed/Refractory LBCL

August 4th 2023

Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

Dr Wakelee on Key Trials With Perioperative Immunotherapy in Early-Stage NSCLC

August 4th 2023

Heather Wakelee, MD, FASCO, discusses the clinical significance of updated data from several key trials evaluating perioperative immunotherapy in early-stage non–small cell lung cancer.

Dr Kwendakwema on the Effects of Financial Toxicity on Treatment Costs in Patients With Cancer

August 3rd 2023

Natasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.

Dr Kremyanskaya on the Rationale for Investigating Rusfertide in Phlebotomy-Dependent PV

August 3rd 2023

Marina Kremyanskaya, MD, PhD, discusses the rationale for investigating rusfertide in the phase 2 REVIVE trial for patients with phlebotomy-dependent polycythemia vera.

Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADT

August 3rd 2023

Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.

Dr Mohty on the Promise of Elranatamab in Relapsed/Refractory Multiple Myeloma

August 3rd 2023

Mohamad Mohty, MD, PhD, discusses the promise of the phase 2 MagnetisMM-3 trial in patients with relapsed/refractory multiple myeloma, which is investigating elranatamab monotherapy in this patient population.

Dr Khan on the Effects of Financial Toxicity on Survival Outcomes in Patients With Cancer

August 3rd 2023

Hiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.

Dr Kim on the Bridging the Gaps in Lung Cancer Meeting

August 3rd 2023

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

Dr Ziegler on Tovorafenib in Pediatric Low-Grade Glioma

August 2nd 2023

David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.

Dr Bhatnagar on Survival Outcomes With MRD Negativity in AML

August 2nd 2023

Bhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.

Dr Danish on the Potential Use of SCINTIX Radiation Technology in Bone and Lung Tumors

August 2nd 2023

Adnan F. Danish, MD, discusses the methodologies behind the use of SCINTIX radiation technology in metastatic bone and lung tumors, detailing how this technology differs from computed tomography or magnetic resonance imaging scans prior to treatment.

Dr Abdou on Considerations Between AKT vs PI3K Inhibition in HR+/HER2– Breast Cancer

August 2nd 2023

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Dr Islam on Updated Safety and Efficacy Data With FDA-Approved BTK Inhibitors in CLL

August 2nd 2023

Prioty Islam, MD, MSc, discusses the impact of the updated safety and efficacy data seen with FDA-approved BTK inhibitors in patients with chronic lymphocytic leukemia.

Dr Das on the Landscape of Current and Emerging ADCs in SCLC

August 2nd 2023

Millie Das, MD, discusses the current landscape of new and emerging ADCs under investigation in small-cell lung cancer and highlights the phase 2 SWOG S1929 study.

Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC

August 2nd 2023

George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.

Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC

August 2nd 2023